A Decade of Dapper: Movember and the Distinguished Gentleman's Ride Gear Up to Celebrate 10 Years of Riding Together for Men's Health
Movember
and
The Distinguished Gentleman's Ride (DGR)
proudly mark 10 years of partnership, riding to raise vital funds that lift the profile of men's health worldwide. On Sunday, May 18th tens of thousands of dapper-dressed bike enthusiasts and men's health advocates will take to the streets in cities worldwide – uniting in a global movement to support prostate cancer research and men's mental health initiatives.
Since its inception in 2012, The Distinguished Gentleman's Ride has brought together motorcycle enthusiasts with a shared passion for riding and making a difference in men's health outcomes. In 2016, Movember became the official charity partner.
To date, over CAD$3.3 million of funds raised have supported 12 men's health projects in Canada. Seven projects are in the prostate cancer space and five are in mental health. Both organizations share the same goal: to bring people together and help change the face of men's health.
DGR has seen more than 500,000 riders over the decade don their finest dapper drip and ride classic and vintage motorcycles in a show of solidarity for raising the profile of men's health. This year, more than 120 countries around the world are participating with 33 rides taking place throughout Canada.
'Ten years of partnership with DGR is a milestone worth celebrating,' said Dan Cooper, Director of Innovation at Movember. 'This event embodies the kind spirit of community and purpose that drives Movember forward. Every year, we see riders uniting behind a common goal and having important conversations shoulder to shoulder, massively contributing to funding the important work we deliver all over the world.'
DGR Founder Mark Hawwa reflects on the impact of the past decade,'What started as a small ride in 64 cities has grown into over 1,000 cities in 2025. Our partnership with Movember has allowed us to turn passion into purpose on a global scale, contributing to funding research and delivering programs for prostate cancer and men's mental health around the world. In the last 10 years, our community has ridden dapper for Movember; and we're excited to see what the next 10 years will bring.'
Beyond the numbers, DGR is about connection - bringing together individuals from all walks of life to challenge stigma and spark crucial conversations about men's health. From riders sharing personal stories to communities rallying behind the cause, the event fosters a powerful sense of solidarity and support.
Toronto rider, Blair Scarlett who is celebrating 10 years of riding with DGR, shares, 'For me, the DGR highlights the need to eliminate the stigma attached to men's mental health while raising the awareness about prostate and testicular cancer. It allows all the DGR participants unite for an amazing cause while doing something we love to do.'
'Every year, the energy on the streets is electric,' says Cooper. 'From the tailored suits to the rumble of vintage motorcycles, it's a sight to behold. But most importantly, it's a reminder that no man should face a health crisis alone.'
To donate or sign up for a DGR near you, visit
gentlemansride.com
. To learn more about where the money goes visit
here
to access the investment report.
Canadian Rides 2025
Berwick, NS
Calgary, AB
Cornwall, ON
Courtenay, BC
Edmonton, AB
Gibsons, BC
Halifax, NS
Hamilton, ON
Kamloops, BC
Kelowna, BC
Kincardine, ON
Ladysmith, BC
Lethbridge, AB
Lucan, ON
Montreal, QC
Nelson, BC
Newmarket, ON
Niagara Falls, ON
North Bay, ON
Ottawa, ON
Parksville, BC
Quebec City, QC
Regina, SK
Saguenay, QC
Saint-Anaclet-de-lessard, QC
Shediac, NB
Sherbrooke, QC
Summerside, PEI
Toronto, ON
Vancouver, BC
Victoria, BC
Whitby, ON
Winnipeg, MB
About Movember
Movember is the leading global men's health charity, funding groundbreaking research and support programs in prostate cancer, testicular cancer, mental health, and suicide prevention. Since 2003, Movember has proudly powered over 1,300 projects worldwide, transforming the lives of boys, men and entire communities across the globe.
About The Distinguished Gentleman's Ride
The Distinguished Gentleman's Ride unites classic and vintage motorcycle riders worldwide to raise funds and awareness for men's health. Founded in Sydney in 2012, DGR has since grown into a global movement, raising over CAD$62.1M for men's health initiatives. For more information, visit
www.gentlemansride.com
.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a26fcabe-bbb9-4b1e-ad61-647baa1ba15e
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
16 minutes ago
- Chicago Tribune
The silent disease that's been killing Americans for decades — And what doctors are doing about it
Heart disease remains the leading cause of death in the U.S., claiming a life every 34 seconds. But beyond heart attacks or other sudden events, a quieter threat is building inside Americans' blood vessels. It's called arterial calcification, an often overlooked driver of serious health complications. Now a breakthrough technology offers hope for better treatment. When arteries become narrowed or hardened due to the buildup of plaque, it's known as atherosclerosis. Over time, these plaques can calcify, meaning they harden into rigid, rocklike deposits that line the inner or middle walls of arteries. This process, called calcification, makes arteries less flexible and more likely to get blocked, raising the risk of heart attacks, strokes and limb loss. Peripheral artery disease is a common result of this process. It happens when narrowed or hardened arteries reduce blood flow to the legs and feet. PAD affects approximately 230 million people worldwide, yet many don't realize it. Arterial calcification can also affect the arteries that supply the heart, leading to coronary artery disease. When blood flow to the heart is restricted, it can cause chest pain, shortness of breath and heart attacks. Annually, the disease results in 17.8 million deaths worldwide. Like PAD, CAD develops silently over time. Once identified, calcified plaques are notoriously hard to treat. Standard procedures can work well for soft plaque. Doctors thread a tiny balloon into the blocked artery, inflate it to compress the blockage, then often insert a metal mesh tube called a stent to keep the vessel open. With calcified arteries, rigid calcium often doesn't budge. Traditional balloons may fail to expand or cause artery tears. Similarly, stents may not fully deploy, increasing procedural complications. In short, older tools try to push through the problem. But next-generation technology uses a different approach: preparing the artery first, helping ensure procedures are safer and more efficient. Enter intravascular lithotripsy, a breakthrough therapy that borrows from an unexpected source: kidney stone treatment. For decades, doctors have used sound waves to break up kidney stones through a minimally invasive procedure. IVL applies the same principle inside the artery, delivering controlled sonic pulses through a modified balloon catheter to gently crack calcium deposits from within. This approach avoids many complications of more aggressive procedures and is considered one of the most promising developments in interventional cardiology. IVL was first approved for coronary use just four years ago, with adoption growing rapidly. One early IVL company quickly became the market leader and was acquired by Johnson & Johnson in 2024 — another sign of the technology's growing importance in cardiovascular Medical is a standout innovator in the IVL space, pushing the boundaries of energy delivery and procedural efficiency to elevate outcomes in peripheral and coronary interventions. 'FastWave Medical's novel IVL platforms offer genuine promise for addressing severely calcified coronary arteries that are difficult to traverse,' says Dr. Kathleen Kearney, medical director of the Cardiac Cath Lab at UWMC Montlake. 'These technological improvements are greatly needed to empower physicians in providing more effective treatment to their patients.' But what makes FastWave particularly noteworthy isn't just its technology; it's who's backing it. Alongside venture investors, physicians — cardiologists, vascular surgeons and interventional radiologists — have invested in the company. Their involvement signals more than financial interest; it reflects confidence in the system's potential to address the daily challenges they face in the cath lab. When physicians invest in medical technology, it demonstrates something powerful: They believe it will genuinely improve their ability to deliver high-quality care. 'FastWave is moving quickly and decisively to become best-in-class in the IVL space,' said Dr. Arthur Lee, director of peripheral vascular services at the Cardiac and Vascular Institute. 'We are excited to support the development of this groundbreaking technology and get it into the hands of those who need it most.' 'Calcified arteries remain one of the most difficult conditions to treat in our field,' added Dr. Amir Kaki, director of mechanical circulatory support and high-risk coronary interventions at Henry Ford St. John Hospital. 'FastWave's IVL platform is a compelling advancement that should provide a more precise, efficient and predictable way to manage complex arterial disease.' As of July 2025, the company holds a total of eight patents, with several more applications underway. These patents span key areas of the technology from energy delivery to catheter design. Early study results are encouraging for the company's dual IVL platforms. In June, FastWave successfully completed initial first-in-human procedures as part of an ongoing feasibility study for its coronary laser-based IVL system. An Investigational Device Exemption is also planned to evaluate its electric IVL system for the treatment of PAD. 'Calcified lesions aren't just a technical challenge — the condition remains one of the most significant barriers to successful peripheral interventions,' said Dr. Sahil Parikh, director of endovascular services at Columbia University Irving Medical Center. 'FastWave's upcoming IDE trial for PAD will give us a chance to assess whether an advanced IVL system can meaningfully improve the lives of patients who suffer from this difficult disease.' Dr. Venita Chandra, clinical professor of surgery at Stanford Health Care, expects the trial to reveal whether FastWave's device will offer doctors a better tool for difficult cases. 'The key question isn't just whether a device works but whether it makes procedures more efficient and provides physicians with a more predictable tool for treating patients with complex arterial disease,' she said. The stakes are rising rapidly. As the population ages and rates of diabetes and obesity continue to climb, more patients will face PAD and CAD. For the most difficult cases, treatment options are quite limited. But innovation is catching up. First-generation IVL introduced a new treatment paradigm; now advanced tools from startups like FastWave promise doctors more ways to treat this disease.
Business Upturn
30-07-2025
- Business Upturn
Treatment.com AI Engages Market Maker
Vancouver, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) — AI Inc. (the 'Company' or 'Treatment') (CSE: TRUE; OTC: TREIF; 939: FRA) has engaged the services of Independent Trading Group ('ITG') pursuant to an agreement dated and starting on July 29, 2025 (the 'Agreement') to provide market-making services in accordance with Canadian Securities Exchange ('CSE') policies. ITG will trade shares of the Company on the CSE and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of the Company's common shares. Under the terms of the Agreement, ITG will receive compensation of CAD $5,500 per month, payable monthly in advance. The Agreement is for an initial term of one month and will renew for additional one-month terms unless terminated by either party with 30 days' notice. There is no performance factors contained in the Agreement and ITG will not receive shares or options as compensation. ITG and the Company are unrelated and unaffiliated entities. Independent Trading Group (ITG) Inc. is a Toronto based CIRO dealer-member that specializes in market making, liquidity provision, agency execution, ultra-low latency connectivity, and bespoke algorithmic trading solutions. Established in 1992, with a focus on market structure, execution and trading, ITG has leveraged its own proprietary technology to deliver high quality liquidity provision and execution services to a broad array of public issuers and institutional investors. About AI Inc. AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment's products and services: or email: [email protected] m FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO [email protected] For media inquiries, contact: [email protected] Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment's expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Hamilton Spectator
29-07-2025
- Hamilton Spectator
Treatment.com AI Engages Market Maker
Vancouver, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) — AI Inc. (the 'Company' or 'Treatment') (CSE: TRUE; OTC: TREIF; 939: FRA) has engaged the services of Independent Trading Group ('ITG') pursuant to an agreement dated and starting on July 29, 2025 (the 'Agreement') to provide market-making services in accordance with Canadian Securities Exchange ('CSE') policies. ITG will trade shares of the Company on the CSE and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of the Company's common shares. Under the terms of the Agreement, ITG will receive compensation of CAD $5,500 per month, payable monthly in advance. The Agreement is for an initial term of one month and will renew for additional one-month terms unless terminated by either party with 30 days' notice. There is no performance factors contained in the Agreement and ITG will not receive shares or options as compensation. ITG and the Company are unrelated and unaffiliated entities. Independent Trading Group (ITG) Inc. is a Toronto based CIRO dealer-member that specializes in market making, liquidity provision, agency execution, ultra-low latency connectivity, and bespoke algorithmic trading solutions. Established in 1992, with a focus on market structure, execution and trading, ITG has leveraged its own proprietary technology to deliver high quality liquidity provision and execution services to a broad array of public issuers and institutional investors. About AI Inc. AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment's products and services: or email: info@ m FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@ For media inquiries, contact: media@ Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment's expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
